Navigation Links
Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
Date:4/29/2009

type 2 diabetes. It is used with metformin, a sulfonylurea, or a thiazolidinedione. BYETTA is not a substitute for insulin in patients whose diabetes requires insulin treatment. BYETTA is not recommended for use in patients with severe problems digesting food or those who have severe disease of the stomach or kidney.

When BYETTA is used with a medicine that contains a sulfonylurea, hypoglycemia (low blood sugar) is a possible side effect. To reduce this possibility, the dose of sulfonylurea medicine may need to be reduced while using BYETTA. Other common side effects with BYETTA include nausea, vomiting, diarrhea, dizziness, headache, feeling jittery, and acid stomach. Nausea is the most common side effect when first starting BYETTA, but decreases over time in most patients.

If patients experience the following severe and persistent symptoms (alone or in combination): abdominal pain, nausea, vomiting, or diarrhea, they should talk to their healthcare provider because these symptoms could be signs of serious medical conditions. BYETTA may reduce appetite, the amount of food eaten, and body weight. No changes in dose are needed for these side effects. These are not all of the side effects from use of BYETTA. A healthcare provider should be consulted about any side effect that is bothersome or does not go away. For full prescribing information, visit www.BYETTA.com.

About Amylin and Lilly

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therap
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
4. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
5. Lilly and Glenmark Pharmaceuticals Announce License Agreement
6. Lilly Receives NCQA Design Certification for Depression Care Management Program
7. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
8. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
9. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
10. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
11. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: ... on Omega-3 therapies for cardiovascular disease (CVD) and ... results for the three months ended March 31, ... Canadian dollars unless otherwise stated. "Pivotal ... its limited financial resources," stated Mr. Eugenio ...
(Date:6/1/2015)... June 1, 2015   Regulus Therapeutics Inc ... leading the discovery and development of innovative medicines ... Xanthopoulos , Ph.D. has resigned as President and ... Regulus, Board of Directors, effective today, to pursue ... M.D., who previously served as Chief Medical Officer ...
(Date:6/1/2015)... , June 1, 2015 The nuclear ... by 2020 at a CAGR of 12.08%. Nuclear medicine ... diseases. The two major types of Nuclear imaging used ... was the mainstream modality for nuclear medicine applications like ... to change because of global shortage of molybdenum-99 isotope ...
Breaking Medicine Technology:Pivotal Therapeutics Announces First Quarter Financial Results 2Pivotal Therapeutics Announces First Quarter Financial Results 3Pivotal Therapeutics Announces First Quarter Financial Results 4Pivotal Therapeutics Announces First Quarter Financial Results 5Regulus' Kleanthis G. Xanthopoulos, Ph.D., to Step Down as President and Chief Executive Officer 2Regulus' Kleanthis G. Xanthopoulos, Ph.D., to Step Down as President and Chief Executive Officer 3Regulus' Kleanthis G. Xanthopoulos, Ph.D., to Step Down as President and Chief Executive Officer 4North America Nuclear Imaging Market - Growth, Trends And Forecasts (2014 - 2019) 2North America Nuclear Imaging Market - Growth, Trends And Forecasts (2014 - 2019) 3
... CYBX ) today announced that the company will report financial results ... year ending April 29, 2011 on Monday, November 22, 2010 at ... discuss those results on the same day at 9:00 AM ET ... Call InstructionsTo listen to the conference call live by telephone dial ...
... 2010 PharmAthene, Inc. (NYSE Amex: PIP ) ... threats, today announced that it has closed its previously announced ... at a price to the public of $3.50 per share. ... yield proceeds, before expenses, of approximately $14.1 million and intends ...
Cached Medicine Technology:Cyberonics Announces Conference Call to Discuss Fiscal Year 2011 Second Quarter Financial Results 2PharmAthene Announces Closing of $15 Million Public Offering 2PharmAthene Announces Closing of $15 Million Public Offering 3
(Date:6/1/2015)... June 02, 2015 The National ... Cade as a 2015-2016 inductee into its VIP ... this prestigious distinction for leadership in business. NAPW is ... boasting more than 700,000 members and over 200 operating ... this important honor,” said NAPW President Star Jones. “Her ...
(Date:6/1/2015)... Carson Energy also announced they have selected ... AdvantaIRA Trust, LLC is the country’s largest self-directed IRA ... positions using IRA’s does 2 things:, 1. It gives ... if there current cash position will not allow for ... Carson and their investors to be able to participate ...
(Date:6/1/2015)... 2015 The Delta Dental Foundation is ... organizations in Michigan, Ohio and Indiana for its Brighter ... 30, 2015 has been set. , Across the tri-state ... organizations that specifically focus on children’s oral health and ... health in adults. Each grant request will be considered ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 EBSCO ... solutions, today introduced DynaMed Plus™ , a cross-platform ... medical professionals. It provides clinicians with the ideal blend ... patient care paths. , DynaMed Plus is a ... and includes the most frequently updated evidence-based content. DynaMed ...
(Date:6/1/2015)... Orlando, Florida (PRWEB) June 01, 2015 ... have generously donated $88,000 of the best superfood ... of the record-breaking floods in Texas. , "Monica ... Adams and Natural News in distributing Living Fuel Super ... victims of the millennial floods in Texas," KC Craichy ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Linda Cade, Senior Product Manager at Sage, Into its VIP Professional Woman of the Year Circle 2Health News:Carson Energy Brings Oil Wells To IRAs 2Health News:Brighter Futures Community Grants Program Seeks to Help Fund Local Oral Health Programs 2Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 2Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 3Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 4Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 2Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 3
... , TUESDAY, Nov. 15 (HealthDay News) -- A novel treatment ... bone health of postmenopausal women who are at high risk ... on a motorized, vibrating platform in the hope of building ... hoped those results might translate to humans, found no benefit ...
... expression test was found to be more effective for ... patients than myocardial perfusion imaging (MPI), a common test ... flow and function of the heart., Study results were ... 2011 conference in Orlando, Fla. , "In this real-world ...
... High school health classes fail to help students refuse ... primarily on testing knowledge, a new study reveals. But ... and to improve health, students had much better responses. In ... sex and felt better able to navigate sexual situations. ...
... , TUESDAY, Nov. 15 (HealthDay News) -- New research suggests ... other people see you at first glance in terms of ... influence your personality, especially in terms of empathy. Or it,s ... way you act. On the other hand, the research is ...
... of problem drinking, a significant decrease in the function of ... is the system that regulates such functions as impulse control ... is seen in men. This is the conclusion of multidisciplinary ... Sahlgrenska Academy at the University of Gothenburg, Sweden. The ...
... TUESDAY, Nov. 15 (HealthDay News) --,Low levels of vitamin D ... stroke, according to one of several new studies on the ... more than 2,000 healthy, postmenopausal white women aged 45 to ... D deficiency had more risk factors for heart disease than ...
Cached Medicine News:Health News:Whole-Body Vibration Doesn't Build Bone After All: Study 2Health News:Blood-based genomic test better than imaging test for ruling out obstructive coronary artery disease 2Health News:Focus on testing hurts students in high school health classes 2Health News:Focus on testing hurts students in high school health classes 3Health News:Does a Gene Make People Seem Kinder? 2Health News:Does a Gene Make People Seem Kinder? 3Health News:Low Vitamin D May Increase Stroke, Heart Attack Risk in Women 2
The new ProteomeX Workstation enables the rapid set up, execution and analysis of multidimensional LC/MS methods, providing you with the best possible technique to characterize your complex proteomic...
Storage temperature: 2 - 8C, linearity: 0 - 700 mg/dL, expected values: 30 - 780 mg/dL. Available with calibrator and number of tests 110....
Alkaline phosphatase FS (DGKC new; 37C). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
For the direct colorimetric determination of alkaline phosphatase in human serum....
Medicine Products: